Recommended first-line targeted molecular therapy regimens for locally advanced disease and metastatic disease include Entrectinib/Larotrectinib (if NTRK gene fusion-positive), Pembrolizumab (if MSI-high, dMMR, or TMB-high [≥10 mut/Mb]), Dabrafenib + trametinib (if BRAF V600E mutation-positive), and Selpercatinib (if RET gene fusion-positive). Here, BRAF is linked to metastatic neoplasm.